Presence of active MRI lesions in patients suspected of non-radiographic axial spondyloarthritis with high disease activity and chance at conversion after a 6-month follow-up period

被引:11
|
作者
Rusman, Tamara [1 ]
John, Marie-Luise B. [1 ]
van der Weijden, Mignon A. C. [1 ]
Boden, Bouke J. H. [2 ]
van der Bijl, Carmella M. A. [1 ]
Bruijnen, Stefan T. G. [1 ]
van der Laken, Conny J. [1 ]
Nurmohamed, Mike T. [1 ,3 ]
van der Horst-Bruinsma, Irene E. [1 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol 3a 64, POB 7057, NL-1007 MB Amsterdam, Netherlands
[2] Onze Lieve Vrouwe Gasthuis OLVG, Radiol, Amsterdam, Netherlands
[3] Reade, Rheumatol, Amsterdam, Netherlands
关键词
Gender; Inflammation; Inflammatory back pain; Magnetic resonance imaging; Spondyloarthropathy; RESONANCE-IMAGING INDEX; SACROILIAC JOINTS; ANKYLOSING-SPONDYLITIS; RESEARCH CONSORTIUM; BACK-PAIN; INFLAMMATION; CRITERIA;
D O I
10.1007/s10067-019-04885-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The primary aim is to evaluate signs of inflammation on MRI of sacroiliac joints (SIJ)/spine in inflammatory back pain (IBP) patients suspected of nr-axSpA with high disease activity. Secondary aims are to describe the onset of new inflammatory lesions at MRI after 6 months and to evaluate gender differences in the presence of inflammation. Method Consecutively, patients with IBP with at least two spondyloarthritis features, high disease activity (BASDAI >= 4), and who were TNFi naive, had a MRI of SIJ and spine. In the absence of active lesions, MRI was repeated after 6 months. MRI images were scored according to the Spondyloarthritis Research Consortium of Canada method. Results Sixty-nine patients were included (53% female), of whom 39% showed signs of inflammation at the first MRI: 30.9% of the SIJ, 19.1% of the spine and 2.4% at both sites, irrespective of the CRP levels. Males more often showed inflammatory signs at the MRI of the SIJ and spine compared with females (45.5% vs. 33.3%). Consistently, the median SPARCC score was higher in males: for SIJ 14.0 (IQR 2.3-25.0) and for spine 11.5 (IQR 8.5-25.6). Only one patient (4.7%) without baseline inflammatory signs showed active lesions of SIJ after 6 months. Conclusions Almost 40% of the IBP patients suspected of nr-axSpA, with high disease activity, showed inflammatory lesions on MRI of SIJ and/or spine, which occurred more often in males compared with females. In the majority (95.3%), an MRI without inflammatory lesions remained negative after 6 months despite high disease activity.
引用
收藏
页码:1521 / 1529
页数:9
相关论文
共 26 条
  • [21] Global Positioning System Use in the Community to Evaluate Improvements in Walking After Revascularization A Prospective Multicenter Study With 6-Month Follow-Up in Patients With Peripheral Arterial Disease
    Gernigon, Marie
    Le Faucheur, Alexis
    Fradin, Dominique
    Noury-Desvaux, Benedicte
    Landron, Cedric
    Mahe, Guillaume
    Abraham, Pierre
    [J]. MEDICINE, 2015, 94 (18)
  • [22] Assessment of metabolic risk factors and heart-healthy lifestyle in atherosclerotic coronary artery disease patients undergoing percutaneous coronary intervention after a 6-month follow-up
    Jazi, Seyed Mohammad Hashemi
    Radmanesh, Armina
    Sadeghi, Masoumeh
    Mansouri, Asieh
    [J]. ADVANCED BIOMEDICAL RESEARCH, 2022, 11 (01): : 15
  • [23] High mortality after discharge among patients with high risk for developing heparin-induced thrombocytopenia or thrombosis: 6-month follow-up results of the complications after thrombocytopenia caused by heparin (CATCH) registry
    Ohman, EM
    Abrams, CS
    Honeycutt, EF
    Becker, RC
    Crespo, EM
    Anstrom, KJ
    Moliterno, DJ
    Rice, L
    Rodgers, JE
    Steinhubl, SR
    Granger, CB
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 411A - 411A
  • [24] 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
    Ivesono, Timothy
    Boydo, Kathleen A.
    Kerro, Rachel S.
    Robles-Zuritao, Jose
    Saunders, Mark P.
    Briggso, Andrew H.
    Cassidyo, Jim
    Hollandero, Niels Henrik
    Taberneroo, Josep
    Haydon, Andrew
    Glimeliuso, Bengt
    Harkino, Andrea
    Allano, Karen
    McQueeno, John
    Pearsono, Sarah
    Waterstono, Ashita
    Medleyo, Louise
    Wilsono, Charles
    Elliso, Richard
    Essapen, Sharadah
    Dhaddao, Amandeep S.
    Harrison, Mark
    Falko, Stephen
    Raoufo, Sherif
    Rees, Charlotte
    Oleseno, Rene K.
    Proppero, David
    Bridgewatero, John
    Azzabio, Ashraf
    Farrugiao, David
    Webbo, Andrew
    Cunninghamo, David
    Hickish, Tamas
    Weavero, Andrew
    Gollins, Simon
    Wasano, Harpreet
    Paulo, James
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2019, 23 (64) : 1 - +
  • [25] Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study
    Arnold, D. L.
    Barnett, M.
    Comi, G.
    Giovannoni, G.
    Pelletier, D.
    Rovira, A.
    Schippling, S.
    Van Wijmeersch, B.
    Margolin, D. H.
    Thangavelu, K.
    Traboulsee, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 329 - 329
  • [26] Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study
    Arnold, Douglas L.
    Barnett, Michael
    Comi, Giancarlo
    Giovannoni, Gavin
    Pelletier, Daniel
    Rovira, Alex
    Schippling, Sven
    Van Wijmeersch, Bart
    Margolin, David H.
    Thangavelu, Karthinathan
    Traboulsee, Anthony
    [J]. NEUROLOGY, 2017, 88